Rotavirus vaccine I321 - Bharat Biotech

Drug Profile

Rotavirus vaccine I321 - Bharat Biotech

Alternative Names: I321 - Bharat Biotech; I321 AGMK; Live attenuated Indian rotavirus vaccine candidate strain I321 - Bharat Biotech

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Indian Institute of Science; Stanford University
  • Developer Bharat Biotech
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rotavirus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rotavirus-infections(Prevention) in USA (PO)
  • 28 Jun 2005 Phase-II clinical trials in Rotavirus infections in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top